Aytu BioPharma, Inc. (Nasdaq: AYTU) reported its fiscal 2027 first quarter operational and financial results for the period ended September 30, 2026. The company announced that due to a pending merger, it will not hold an earnings conference call to discuss the results.
For the first quarter of fiscal 2027, Aytu reported net revenue of $14.8 million, a 6.9% increase compared to $13.9 million in the prior-year period. The company’s revenue was driven by its ADHD and Pediatric portfolios, though the ADHD portfolio saw a decrease compared to the prior year due to reduced promotional emphasis and generic competition.
Key financial metrics for the quarter included:
- EXXUA Net Revenue: $4.9 million, representing a 24.5% increase from the prior quarter and a significant increase from the prior-year period where revenue was $3.9 million.
- ADHD Portfolio Net Revenue: $7.7 million, down from $13.2 million in the prior year.
- Pediatric Portfolio Net Revenue: $2.2 million, up from $0.7 million in the prior year.
- Net Loss: ($3.9) million, or ($0.20) per share, compared to net income of $2.0 million, or $0.21 per share, in the prior year.
- Adjusted EBITDA: ($2.6) million, compared to ($0.6) million in the prior year.
- Cash and Cash Equivalents: $25.5 million at September 30, 2026.
On November 16, 2026, Aytu announced it entered into a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc. Under the terms of the agreement, Rosemont will acquire Aytu through a cash tender offer for $2.70 per share, followed by a merger. The total consideration is approximately $56 million on a fully-diluted basis. The transaction is expected to be completed by the end of calendar 2026, subject to the tender of a majority of the outstanding shares of Aytu common stock and the satisfaction of customary closing conditions.